Abbott ’s FreeStyle Libre Catches Sanofi’s Eye in New Collaboration
Two powerhouses in pharma and medtech are working together to help people with diabetes better manage their condition. Abbott Laboratories and Sanofi will collaborate to integrate glucose sensing and insulin delivery technologies.
The two companies will take an innovative approach to connected care by developing tools that combine the Abbott Park, Il-based companyâs FreeStyle Libre technology with Paris-based Sanofiâ²s insulin dosing information.
Initially, the collaboration enables data sharing, at the consent of the user, between Abbottâ²s FreeStyle Libre mobile app and cloud software and Sanofiâ²s connected insulin pens, apps, and cloud software that are currently in development. This data sharing will enable both people with diabetes and their doctors to make better-informed treatment decisions around medication, nutrition, and lifestyle.
"Sanofi and Abbott aim to provide this to people with diabetes within the next few years, pending local in-country regulatory approvals," Abbott told MD+DI in an email. "We will share details on launch and timing in the future closer to the launch dates."
The Freestyle Libre, which received approval by FDA in 2017, has been a massive success. Abbott recorded sales of $430 million for Libre in 2Q19 analysts expect it to approach $2 billion for the year, based on consensus, according to Matthew Taylor, an analyst for UBS. The Freestyle Libre is a game-changing...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: IVD Business Source Type: news
More News: Diabetes | Diabetes Type 2 | Endocrinology | Insulin | Medical Devices | Nutrition | Partnerships | Pharmaceuticals